temelimab   Click here for help

GtoPdb Ligand ID: 11530

Synonyms: GNbAC1
Immunopharmacology Ligand
Compound class: Antibody
Comment: Temelimab (GNbAC1) is a humanised IgG4κ monoclonal antibody that binds to the extracellular domain of the human endogenous retroviral envelope protein HERV-W-Env [3-5].
SARS-CoV-2: blocking HERV-W-Env has been proposed as a mechanism to target pathologic inflammation in COVID-19 patients, based on evidence of ERV-W-Env's immunopathogenic role in immune-mediated and neurological diseases and elevated HERV-W-Env expression in T cells from SARS-CoV-2 infected individuals [1].
Click here for help
1. Balestrieri E, Minutolo A, Petrone V, Fanelli M, Iannetta M, Malagnino V, Zordan M, Vitale P, Charvet B, Horvat B et al.. (2021)
Evidence of the pathogenic HERV-W envelope expression in T lymphocytes in association with the respiratory outcome of COVID-19 patients.
EBioMedicine,: 103341 [Epub ahead of print]. [PMID:33867312]
2. Curtin F, Champion B, Davoren P, Duke S, Ekinci EI, Gilfillan C, Morbey C, Nathow T, O'Moore-Sullivan T, O'Neal D et al.. (2020)
A safety and pharmacodynamics study of temelimab, an antipathogenic human endogenous retrovirus type W envelope monoclonal antibody, in patients with type 1 diabetes.
Diabetes Obes Metab, 22 (7): 1111-1121. [PMID:32077207]
3. Curtin F, Lang AB, Perron H, Laumonier M, Vidal V, Porchet HC, Hartung HP. (2012)
GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
Clin Ther, 34 (12): 2268-78. [PMID:23200102]
4. Curtin F, Perron H, Kromminga A, Porchet H, Lang AB. (2015)
Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.
MAbs, 7 (1): 265-75. [PMID:25427053]
5. Kornmann G, Curtin F. (2020)
Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review.
Drug Saf, 43 (12): 1287-1296. [PMID:32794123]